| Alere's New Collaborative Care Solutions® to Focus on Enhancing Interactions Between Patients and Physicians (PR Newswire) With the goal of creating the industry standard for connecting patients and their physician-led care teams, Alere today announced the formation of a new strategic product line, Collaborative Care Solutions®.  The new product line will be focused on supporting physicians and provider groups wanting to expand their practices via patient-centered medical homes or accountable care organizations -- key care models designed to realize better outcomes and more cost-effective care. us.rd.yahoo.com |
FDA Warns Pfizer On Reporting Failures The FDA warned Pfizer about its failure to properly follow the agency's rules on reporting adverse events involving products. online.wsj.com |
Inspire Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript Inspire Pharmaceuticals, Inc. (ISPH)Q2 2010 Earnings Call TranscriptAugust 5, 2010 8:00 am ETComplete Story » seekingalpha.com |
Arena Pharma: Using Options to Trade on FDA's Decision for Key Obesity Drug Joe Kunkle submits:Arena Pharma (ARNA) is a Biotech that everyone is watching into the September 16th FDA Panel that will vote on approval of its key obesity drug, Lorcaserin. The actual PDUFA date is set for October 22nd.In the race to become the top obesity drug there are a two other companies competing for ownership of the obesity drug market, a potential massive cash cow. Vivus (VVUS) had its FDA Panel for Qnexa in July and shares fell from $13 to $5 as the Panel voted against approval on safety concerns, although many had seen Vivus' drug as the most effective, and the leader in the group. Orexigen (OREX) is the other player, with Contrave, set for FDA Panel review on December 7th 2010 and a final FDA decision by the end of January 2011.Complete Story » seekingalpha.com |
Boston Scientific CEO Discusses Q3 2010 Results - Earnings Call Transcript Boston Scientific Corporation (BSX)Q3 2010 Earnings CallOctober 19, 2010 5:30 pm ETComplete Story » seekingalpha.com |